Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash-to-Debt 0.29
LNTH's Cash-to-Debt is ranked lower than
84% of the 261 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.52 vs. LNTH: 0.29 )
Ranked among companies with meaningful Cash-to-Debt only.
LNTH' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.05  Med: 0.08 Max: 0.29
Current: 0.29
0.05
0.29
Equity-to-Asset 0.06
LNTH's Equity-to-Asset is ranked lower than
95% of the 239 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.61 vs. LNTH: 0.06 )
Ranked among companies with meaningful Equity-to-Asset only.
LNTH' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.98  Med: -0.65 Max: 0.06
Current: 0.06
-0.98
0.06
Debt-to-Equity 11.51
LNTH's Debt-to-Equity is ranked lower than
99% of the 164 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 0.36 vs. LNTH: 11.51 )
Ranked among companies with meaningful Debt-to-Equity only.
LNTH' s Debt-to-Equity Range Over the Past 10 Years
Min: -2.61  Med: -1.82 Max: 11.51
Current: 11.51
-2.61
11.51
Debt-to-EBITDA 3.47
LNTH's Debt-to-EBITDA is ranked lower than
72% of the 116 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.77 vs. LNTH: 3.47 )
Ranked among companies with meaningful Debt-to-EBITDA only.
LNTH' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 3.47  Med: 7.19 Max: 49.9
Current: 3.47
3.47
49.9
Interest Coverage 2.82
LNTH's Interest Coverage is ranked lower than
91% of the 163 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 76.01 vs. LNTH: 2.82 )
Ranked among companies with meaningful Interest Coverage only.
LNTH' s Interest Coverage Range Over the Past 10 Years
Min: 0.93  Med: 1.5 Max: 2.82
Current: 2.82
0.93
2.82
Piotroski F-Score: 7
Altman Z-Score: 1.92
Beneish M-Score: -1.23
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating Margin % 15.65
LNTH's Operating Margin % is ranked higher than
84% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.59 vs. LNTH: 15.65 )
Ranked among companies with meaningful Operating Margin % only.
LNTH' s Operating Margin % Range Over the Past 10 Years
Min: -12.27  Med: 13.07 Max: 16.63
Current: 15.65
-12.27
16.63
Net Margin % 37.23
LNTH's Net Margin % is ranked higher than
99% of the 241 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -2.48 vs. LNTH: 37.23 )
Ranked among companies with meaningful Net Margin % only.
LNTH' s Net Margin % Range Over the Past 10 Years
Min: -38.52  Med: -5.02 Max: 37.23
Current: 37.23
-38.52
37.23
ROA % 42.90
LNTH's ROA % is ranked higher than
98% of the 262 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -4.54 vs. LNTH: 42.90 )
Ranked among companies with meaningful ROA % only.
LNTH' s ROA % Range Over the Past 10 Years
Min: -25.87  Med: -3.74 Max: 42.9
Current: 42.9
-25.87
42.9
ROC (Joel Greenblatt) % 48.74
LNTH's ROC (Joel Greenblatt) % is ranked higher than
85% of the 259 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -9.57 vs. LNTH: 48.74 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
LNTH' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -15.57  Med: 28.69 Max: 49.57
Current: 48.74
-15.57
49.57
3-Year Revenue Growth Rate -6.10
LNTH's 3-Year Revenue Growth Rate is ranked lower than
72% of the 182 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.80 vs. LNTH: -6.10 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
LNTH' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -6.1
Current: -6.1
3-Year EBITDA Growth Rate -0.40
LNTH's 3-Year EBITDA Growth Rate is ranked lower than
67% of the 178 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 10.10 vs. LNTH: -0.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
LNTH' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: 0 Max: -0.4
Current: -0.4
GuruFocus has detected 2 Warning Signs with Lantheus Holdings Inc LNTH.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LNTH's 30-Y Financials

Financials (Next Earnings Date: 2018-08-01)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2017

LNTH Guru Trades in Q1 2017

Paul Tudor Jones 75,000 sh (New)
Jim Simons 613,800 sh (+56.02%)
Steven Cohen Sold Out
Joel Greenblatt 11,771 sh (-51.21%)
» More
Q2 2017

LNTH Guru Trades in Q2 2017

Chuck Royce 277,382 sh (New)
Jim Simons 691,000 sh (+12.58%)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
» More
Q3 2017

LNTH Guru Trades in Q3 2017

Ken Fisher 101,043 sh (New)
Joel Greenblatt 45,226 sh (New)
Jim Simons 627,100 sh (-9.25%)
Chuck Royce 203,168 sh (-26.76%)
» More
Q4 2017

LNTH Guru Trades in Q4 2017

Jeremy Grantham 30,900 sh (New)
Jim Simons 903,400 sh (+44.06%)
Ken Fisher 117,973 sh (+16.76%)
Joel Greenblatt Sold Out
Chuck Royce 122,616 sh (-39.65%)
» More
» Details

Insider Trades

Latest Guru Trades with LNTH

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Ken Fisher 2018-03-31 Add 44.16%$14.85 - $24.3 $ 17.30-12%170,075
Ken Fisher 2017-12-31 Add 16.76%$17.4 - $23.4 $ 17.30-15%117,973
Joel Greenblatt 2017-12-31 Sold Out 0.01%$17.4 - $23.4 $ 17.30-15%0
Ken Fisher 2017-09-30 New Buy$15.5 - $19.55 $ 17.30-2%101,043
Joel Greenblatt 2017-09-30 New Buy0.01%$15.5 - $19.55 $ 17.30-2%45,226
Joel Greenblatt 2017-06-30 Sold Out $10.85 - $17.4 $ 17.3018%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Medical Diagnostics & Research » Diagnostics & Research    NAICS: 621511    SIC: 8071
Compare:BSP:AALR3, SZSE:300289, NAS:HSKA, NAS:VIVO, LSE:IDHC, NAS:NEO, NAS:RDNT, NAS:NTRA, SHSE:603716, NAS:SRDX, NSE:THYROCARE, SZSE:300639, NYSE:ARA, TSE:2309, OSTO:CEVI, AMEX:SENS, XBRU:BCART, HKSE:02393, NAS:NRCIA, NYSE:NVTA » details
Traded in other countries:0L8.Germany,
Headquarter Location:USA
Lantheus Holdings Inc develops diagnostic products for the healthcare sector. Its chief product is imaging agents used by physicians in diagnostic procedures such as cardiac ultrasounds and X-ray imaging.

Lantheus Holdings Inc caters to the United States healthcare sector with the development of diagnostic products. Its imaging products and agents assist clinicians in the diagnosis and treatment of cardiovascular and other diseases. Its agents are typically non-radioactive compounds that are used in diagnostic procedures, such as cardiac ultrasounds, or echocardiograms, x-ray imaging used by physicians to progress the clarity of the diagnostic image. The company's portfolio of imaging products includes medical radiopharmaceuticals such as DEFINITY, TechneLite, Xenon Xe 133 Gas, Cardiolite, and Neurolite. Its revenue is generated from the sales of diagnostic imaging agents to wholesalers, distributors radiopharmacies and directly to hospitals and clinics predominantly in the United States.

Ratios

vs
industry
vs
history
PE Ratio 5.45
LNTH's PE Ratio is ranked higher than
97% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.00 vs. LNTH: 5.45 )
Ranked among companies with meaningful PE Ratio only.
LNTH' s PE Ratio Range Over the Past 10 Years
Min: 2.23  Med: 10.6 Max: 28.9
Current: 5.45
2.23
28.9
Forward PE Ratio 20.16
LNTH's Forward PE Ratio is ranked higher than
87% of the 40 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 9999.00 vs. LNTH: 20.16 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 5.45
LNTH's PE Ratio without NRI is ranked higher than
97% of the 113 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 35.56 vs. LNTH: 5.45 )
Ranked among companies with meaningful PE Ratio without NRI only.
LNTH' s PE Ratio without NRI Range Over the Past 10 Years
Min: 2.23  Med: 10.6 Max: 28.9
Current: 5.45
2.23
28.9
PB Ratio 28.02
LNTH's PB Ratio is ranked lower than
98% of the 245 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.02 vs. LNTH: 28.02 )
Ranked among companies with meaningful PB Ratio only.
LNTH' s PB Ratio Range Over the Past 10 Years
Min: 24.88  Med: 32.74 Max: 38.25
Current: 28.02
24.88
38.25
PS Ratio 2.06
LNTH's PS Ratio is ranked higher than
74% of the 230 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 3.81 vs. LNTH: 2.06 )
Ranked among companies with meaningful PS Ratio only.
LNTH' s PS Ratio Range Over the Past 10 Years
Min: 0.16  Med: 0.94 Max: 2.76
Current: 2.06
0.16
2.76
Price-to-Free-Cash-Flow 18.09
LNTH's Price-to-Free-Cash-Flow is ranked higher than
81% of the 80 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 29.22 vs. LNTH: 18.09 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
LNTH' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 2.25  Med: 15.62 Max: 67.89
Current: 18.09
2.25
67.89
Price-to-Operating-Cash-Flow 12.29
LNTH's Price-to-Operating-Cash-Flow is ranked higher than
82% of the 97 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 19.94 vs. LNTH: 12.29 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
LNTH' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 1.71  Med: 11.24 Max: 536.92
Current: 12.29
1.71
536.92
EV-to-EBIT 14.60
LNTH's EV-to-EBIT is ranked higher than
82% of the 118 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 25.06 vs. LNTH: 14.60 )
Ranked among companies with meaningful EV-to-EBIT only.
LNTH' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.6  Med: 16.5 Max: 37.4
Current: 14.6
8.6
37.4
EV-to-EBITDA 10.96
LNTH's EV-to-EBITDA is ranked higher than
80% of the 132 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 20.75 vs. LNTH: 10.96 )
Ranked among companies with meaningful EV-to-EBITDA only.
LNTH' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.3  Med: 10.8 Max: 14.6
Current: 10.96
6.3
14.6
EV-to-Revenue 2.58
LNTH's EV-to-Revenue is ranked higher than
72% of the 242 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 4.24 vs. LNTH: 2.58 )
Ranked among companies with meaningful EV-to-Revenue only.
LNTH' s EV-to-Revenue Range Over the Past 10 Years
Min: 1.2  Med: 1.8 Max: 3.4
Current: 2.58
1.2
3.4
Current Ratio 3.16
LNTH's Current Ratio is ranked higher than
59% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.58 vs. LNTH: 3.16 )
Ranked among companies with meaningful Current Ratio only.
LNTH' s Current Ratio Range Over the Past 10 Years
Min: 1.42  Med: 2.13 Max: 3.16
Current: 3.16
1.42
3.16
Quick Ratio 2.60
LNTH's Quick Ratio is ranked higher than
58% of the 250 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 2.14 vs. LNTH: 2.60 )
Ranked among companies with meaningful Quick Ratio only.
LNTH' s Quick Ratio Range Over the Past 10 Years
Min: 1.1  Med: 1.75 Max: 2.6
Current: 2.6
1.1
2.6
Days Inventory 46.45
LNTH's Days Inventory is ranked higher than
66% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 79.76 vs. LNTH: 46.45 )
Ranked among companies with meaningful Days Inventory only.
LNTH' s Days Inventory Range Over the Past 10 Years
Min: 15.47  Med: 35.6 Max: 47.14
Current: 46.45
15.47
47.14
Days Sales Outstanding 44.34
LNTH's Days Sales Outstanding is ranked higher than
73% of the 204 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 67.51 vs. LNTH: 44.34 )
Ranked among companies with meaningful Days Sales Outstanding only.
LNTH' s Days Sales Outstanding Range Over the Past 10 Years
Min: 44.34  Med: 48.23 Max: 52.42
Current: 44.34
44.34
52.42
Days Payable 37.66
LNTH's Days Payable is ranked lower than
73% of the 187 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 63.34 vs. LNTH: 37.66 )
Ranked among companies with meaningful Days Payable only.
LNTH' s Days Payable Range Over the Past 10 Years
Min: 26.94  Med: 32.48 Max: 42.13
Current: 37.66
26.94
42.13

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -8.90
LNTH's 3-Year Average Share Buyback Ratio is ranked lower than
56% of the 180 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -7.90 vs. LNTH: -8.90 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LNTH' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -8.9  Med: 0 Max: 0
Current: -8.9
-8.9
0

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 2.16
LNTH's Price-to-Median-PS-Value is ranked lower than
84% of the 193 Companies
in the Global Diagnostics & Research industry.

( Industry Median: 1.01 vs. LNTH: 2.16 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
LNTH' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.31  Med: 0.98 Max: 2.55
Current: 2.16
0.31
2.55
Earnings Yield (Greenblatt) % 6.87
LNTH's Earnings Yield (Greenblatt) % is ranked higher than
92% of the 265 Companies
in the Global Diagnostics & Research industry.

( Industry Median: -0.98 vs. LNTH: 6.87 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
LNTH' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 2.7  Med: 6.1 Max: 11.6
Current: 6.87
2.7
11.6

More Statistics

Revenue (TTM) (Mil) $331.38
EPS (TTM) $ 3.18
Volatility51.37%
52-Week Range $11.53 - 24.45
Shares Outstanding (Mil)37.93

Analyst Estimate

Dec18
Revenue (Mil $)
EBIT (Mil $)
EBITDA (Mil $)
EPS ($) 1.02
EPS without NRI ($) 1.02
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)

Piotroski F-Score Details

Piotroski F-Score: 77
Positive ROAY
Positive CFROAY
Higher ROA yoyY
CFROA > ROAN
Lower Leverage yoyY
Higher Current Ratio yoyY
Less Shares Outstanding yoyN
Higher Gross Margin yoyY
Higher Asset Turnover yoyY

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}